Pfizer
PFE
$28.00
+1.82%
Pfizer Inc. is one of the world's largest pharmaceutical companies, developing and commercializing prescription medicines and vaccines across therapeutic areas including oncology, immunology, cardiology, and internal medicine, with flagship products such as the Prevnar pneumococcal vaccine and the anticoagulant Eliquis. The company operates primarily through its Biopharma segment, which generated $14.66 billion of the $15.03 billion in most recent quarterly revenue, and it maintains a global footprint with roughly 40% of sales derived internationally, including a significant emerging-markets presence. The current investor narrative centers on whether Pfizer can execute a credible post-COVID turnaround, with recent headlines highlighting a strong August driven by earnings beats and regulatory wins alongside intensifying competition in the obesity space, where its berobenatide candidate is viewed as a potential growth driver pending Phase 3 data. Debate also persists around patent cliffs, pipeline execution risk, and the sustainability of its dividend, which shapes the stock's identity as a high-yield value holding rather than a growth compounder.…
PFE
Pfizer
$28.00
Related headlines
Investment Opinion: Should I buy PFE Today?
The synthesized recommendation is Hold, with a thesis that Pfizer offers deep value and a high dividend yield but faces significant earnings volatility and pipeline execution risk that currently offset its upside potential. The analyst consensus rating of 'buy' (mean 2.46) and average target price of $28.91 imply only 4.0% upside, reflecting muted conviction and aligning with a Hold stance. Supporting evidence includes the forward PE of 9.60x, which is well below the market and typical large-cap pharma multiples, suggesting undervaluation if earnings normalize to the consensus EPS of $2.44. Revenue growth is modest at 2.6% year-over-year, but gross margin expanded to 72.78% and operating margin is a healthy 24.67%, indicating core profitability. Free cash flow is robust at $10.99 billion TTM, but the dividend payout ratio of 125.75% raises sustainability concerns. The implied upside to the high analyst target of $35.75 is 28.6%, but this requires successful pipeline execution and multiple expansion. Key risks include the unsustainable dividend, competitive threats in obesity, and earnings volatility, as evidenced by the Q2 2026 net loss. The rating would upgrade to Buy if forward EPS estimates are met and the dividend is covered by cash flow, or downgrade to Sell if revenue growth turns negative or the dividend is cut. Relative to its history, PFE's PS ratio of 2.26x is near multi-year lows, suggesting it is undervalued, but the discount reflects genuine growth challenges.
Sign up to view all
PFE 12-Month Price Forecast
Pfizer presents a balanced risk/reward profile, with deep value on forward earnings offset by earnings volatility and dividend sustainability risks. The stock's low beta of 0.299 makes it a defensive holding, but its 12-month relative underperformance of -12.35 percentage points versus the S&P 500 highlights weak momentum. The key factor is whether Pfizer can achieve the consensus EPS of $2.44; success would likely drive the stock toward the bull case, while failure could push it to the bear case. I would upgrade to bullish if berobenatide Phase 3 data is positive and dividend coverage improves, or downgrade to bearish if earnings miss and the dividend is cut. Currently, the neutral stance reflects the balance between attractive valuation and significant execution risks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $28.91 and implied upside of +3.3% versus the current price.
Average Target
$28.91
0 analysts
Implied Upside
+3.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$25 - $36
Analyst target range
Pfizer is covered by 26 analysts with a consensus recommendation of "buy" (recommendation mean of 2.46 on a scale where lower is more bullish), and an average target price of $28.91. Against the current price of $27.80, this implies approximately 4.0% upside to the consensus target, a modest return that suggests the consensus is only mildly bullish and largely reflects the stock's low-beta, income-oriented profile rather than strong conviction in near-term appreciation. The consensus leans neutral-to-constructive rather than aggressively bullish, consistent with the mixed institutional ratings, which show a preponderance of Hold/Neutral ratings from HSBC, B of A Securities, JP Morgan, Cantor Fitzgerald, and Citigroup, offset by Buy/Outperform ratings from Guggenheim and BMO Capital. The target range spans from a low of $25.00 to a high of $35.75, a spread of $10.75 or roughly 43% of the low target, signaling meaningful disagreement about the company's trajectory. The high target of $35.75 implies roughly 28.6% upside and would require multiple expansion plus successful pipeline execution, particularly in obesity and oncology, along with resolution of patent-cliff concerns; the low target of $25.00 implies about 10.1% downside and prices in margin compression, continued earnings volatility, and competitive share loss. Institutional rating actions show a mild negative drift, with HSBC downgrading from Buy to Hold on July 6, 2026, and RBC Capital raising its rating from Underperform to Sector Perform on June 10, 2026, while most firms maintained existing Neutral or Buy stances. The wide target spread combined with the low beta of 0.299 and the modest 4.0% implied upside suggests limited near-term catalyst-driven upside, with the stock likely to remain range-bound until clearer evidence of earnings normalization and pipeline success emerges.
Bulls vs Bears: PFE Investment Factors
The bear case currently has slightly stronger evidence due to Pfizer's earnings volatility, unsustainable dividend payout, and competitive pressures, which are concrete near-term concerns. However, the bull case is underpinned by deep value (forward PE of 9.60x), robust gross margins (72.78%), and pipeline optionality in obesity, offering a favorable risk/reward if execution improves. The most critical tension is whether Pfizer can normalize earnings to justify the forward EPS estimate of $2.44; if it does, the stock could re-rate significantly, but failure would likely lead to further multiple compression. With a beta of 0.299, PFE is a defensive holding, but its 6.91% yield is at risk if cash flow doesn't cover dividends. Overall, the debate hinges on pipeline execution and earnings recovery, making it a show-me story.
Bullish
- Deep value on forward earnings: PFE trades at a forward PE of just 9.60x versus a trailing PE of 18.31x, implying the market expects EPS to surge from $0.055 TTM to $2.44 consensus. This massive gap suggests deep undervaluation if earnings normalize, especially with a PS ratio of 2.26x near multi-year lows (vs. 11.84x in Q4 2022).
- Robust gross margins and operating profitability: Gross margin expanded to 72.78% in Q2 2026 from 64.29% a year ago, and operating margin stands at 24.67% with $4.71 billion in operating income. The core business remains highly profitable, and the recent net loss was driven by non-operating items, not operational deterioration.
- Attractive dividend yield with defensive beta: PFE offers a 6.91% dividend yield, far above the market average, supported by $10.99 billion in trailing free cash flow. Its beta of 0.299 means it moves roughly 70% less than the market, making it a low-volatility income holding with potential for capital appreciation.
- Obesity pipeline optionality: Pfizer's berobenatide obesity candidate is viewed as a potential growth driver pending Phase 3 data, as highlighted in recent news. Success in this multi-billion-dollar market could transform Pfizer's growth trajectory and justify multiple expansion toward the analyst high target of $35.75.
Bearish
- Earnings volatility and recent net loss: PFE posted a net loss of $246 million in Q2 2026 (EPS -$0.0432), a sharp reversal from $2.69 billion profit in Q1 2026. This volatility stems from a $5.36 billion swing in other income/expenses, highlighting earnings unpredictability and reliance on non-operating items.
- Dividend payout unsustainable: The dividend payout ratio is 125.75%, meaning Pfizer pays out more in dividends than it earns. In Q2 2026, it paid $2.45 billion in dividends against only $835 million in operating cash flow, raising concerns about the sustainability of the 6.91% yield.
- Patent cliffs and competitive pressures: Pfizer faces patent expirations on key drugs like Eliquis and Prevnar, with competition intensifying in obesity from Eli Lilly and Novo Nordisk. Recent news highlights LLY's European approval for an oral weight-loss drug, underscoring the competitive threat to Pfizer's pipeline.
- Weak relative performance and uneven recovery: PFE has underperformed the S&P 500 by 12.35 percentage points over the past year, with a 2.66% gain versus SPY's 15.01%. The six-month change is -1.84% with relative strength of -19.19, indicating a fragile recovery that could stall.
PFE Technical Analysis
Pfizer is in a broad recovery phase rather than a sustained uptrend, with the shares up just 2.66% over the past year while the S&P 500 gained 15.01%, producing a relative strength deficit of -12.35 percentage points over 12 months. At a current price of $27.80, the stock sits at approximately 74.8% of its 52-week range (low of $23.62, high of $29.21), positioning it in the upper-middle portion of its band but still about 4.8% below the high. This positioning suggests improving sentiment without overextension, consistent with a base-building recovery rather than a momentum chase. Recent momentum is mixed and diverging from the longer-term trend: the stock is down 4.20% over the past month versus a 0.59% gain for SPY (relative strength of -4.79), yet it is up 14.31% over three months, outperforming SPY's 3.34% by nearly 11 percentage points. The one-month pullback from the September 2 peak of $29.02 looks like a consolidation within a stronger intermediate uptrend, though the six-month change of -1.84% and relative strength of -19.19 versus SPY over that window show the recovery has been uneven and recent. Key levels are well defined: support rests at the 52-week low of $23.62, with intermediate support around the $27.46-$27.55 zone where the stock consolidated in mid-September, while resistance sits at the 52-week high of $29.21. A breakout above $29.21 would confirm the recovery and likely invite momentum buyers, whereas a breakdown below $23.62 would signal a failed base and renewed downtrend. Volatility is remarkably low for a single stock, with a beta of just 0.299, meaning Pfizer moves roughly 70% less than the market, which supports defensive position sizing but also limits upside torque; the maximum drawdown of -17.09% over the period reinforces its role as a lower-volatility, income-oriented holding.
Beta
0.28
0.28x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$24-$29
Price range past year
Annual Return
+6.6%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.9% |
| 3m | +15.5% | +3.4% |
| 6m | +4.0% | +14.4% |
| 1y | +6.6% | +16.2% |
| ytd | +11.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory is modestly growing but uneven, with most recent quarterly revenue of $15.03 billion representing 2.6% year-over-year growth against the prior-year quarter's $14.65 billion. The multi-quarter trend shows lumpy performance: revenue rose from $14.45 billion in Q1 2026 to $15.03 billion in Q2 2026, but declined from $17.56 billion in Q4 2025, reflecting seasonality and the loss of COVID-related sales. The Biopharma segment dominates at $14.66 billion of the total, with the corporate non-segment reconciling item contributing $373 million, indicating a highly concentrated, single-segment business model where pipeline execution in core therapeutic areas drives the entire growth story. Profitability is volatile and currently impaired: the most recent quarter posted a net loss of $246 million with a net margin of -1.64%, a sharp reversal from Q1 2026's $2.69 billion profit and 18.60% net margin. Gross margin remains robust at 72.78% in Q2 2026, up from 67.26% in Q1 2026 and 64.29% in the year-ago quarter, and the operating margin of 24.67% (with Q2 operating income of $4.71 billion) shows the core business is profitable before a $5.36 billion swing in other income/expenses and a $667 million interest expense that pushed pre-tax income to -$653 million. The gap between operating income and net income highlights that non-operating items, not operational deterioration, are driving the loss. The balance sheet is leveraged but manageable, with a debt-to-equity ratio of 0.78 and a current ratio of 1.16, while free cash flow on a trailing-twelve-month basis is a healthy $10.99 billion. However, quarterly free cash flow has been erratic, falling to just $302 million in Q2 2026 from $2.18 billion in Q1 2026, and the company paid $2.45 billion in dividends during the quarter against operating cash flow of only $835 million, a payout that is not covered by quarterly cash generation. ROE of 8.99% and ROA of 5.78% are modest for a large-cap pharmaceutical, and the dividend payout ratio of 125.75% signals the dividend is currently being funded beyond earnings, a sustainability concern that income investors must monitor.
Quarterly Revenue
$15.0B
2026-06
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
72.8%
Latest Quarter
Free Cash Flow
$11.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Because Pfizer's trailing net income is positive on a TTM basis (EPS of $0.055), the PE ratio is the appropriate primary metric, and the trailing PE of 18.31x compares to a forward PE of just 9.60x. The enormous gap between trailing and forward multiples implies the market expects a dramatic earnings recovery, with consensus estimated EPS of $2.44 for the forward period versus the depressed trailing figure, a roughly 44x increase in earnings power that reflects the normalization of non-operating charges rather than operational transformation. On a price-to-sales basis, the stock trades at 2.26x, and its EV/EBITDA of 13.76x and EV/Sales of 3.33x provide a fuller picture of a company valued modestly relative to its revenue base. Peer comparison is difficult without explicit industry average data in the provided inputs, but Pfizer's 2.26x PS ratio and 1.64x price-to-book ratio are low in absolute terms for a large-cap pharmaceutical with a 70.33% gross margin and 12.42% net margin, suggesting the market is pricing in patent-cliff risk and pipeline uncertainty. The forward PE of 9.60x is well below the broader market and typical large-cap pharma multiples in the mid-teens, implying a substantial discount that would only be justified if earnings estimates prove overly optimistic. Historically, Pfizer's own valuation has compressed dramatically: its PS ratio was 11.84x in Q4 2022 and 15.91x in Q2 2023, versus just 2.26x today, while its PE ranged from 7.17x to 24.43x across 2021-2022 and now sits at 18.31x trailing. The current PS ratio is near the bottom of its multi-year band, which could signal a value opportunity if earnings normalize, but the persistent compression also reflects genuine deterioration in growth prospects and the market's skepticism about the durability of Pfizer's post-COVID earnings base.
PE
18.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, primarily due to earnings volatility and dividend sustainability. Pfizer reported a net loss of $246 million in Q2 2026, with a net margin of -1.64%, a sharp reversal from Q1 2026's $2.69 billion profit. The dividend payout ratio of 125.75% and quarterly dividend payments of $2.45 billion against operating cash flow of only $835 million indicate the dividend is not covered by cash generation, posing a risk of a cut. Additionally, debt-to-equity of 0.78 and interest expense of $667 million add financial leverage, while revenue concentration in the Biopharma segment ($14.66 billion of $15.03 billion) heightens dependence on pipeline success. Market and competitive risks include valuation compression if earnings disappoint, given the forward PE of 9.60x relies on optimistic EPS estimates. The stock's low beta of 0.299 reduces market correlation but also limits upside torque, and its 12-month relative underperformance of -12.35 percentage points versus the S&P 500 reflects waning investor confidence. Intensifying competition in obesity from Eli Lilly and Novo Nordisk, as highlighted in recent news, threatens Pfizer's berobenatide opportunity, while patent cliffs on key drugs like Eliquis loom. Regulatory headwinds and sector rotation away from healthcare could further pressure the stock. The worst-case scenario involves a failed Phase 3 trial for berobenatide, a dividend cut, and continued earnings misses, triggering a sell-off to the 52-week low of $23.62, representing a 15.0% decline from the current price of $27.80. If analyst bear-case target of $25.00 is breached, losses could reach 10.1%, but a more severe outcome could see the stock test historical support levels, with a maximum drawdown of -17.09% observed over the past period. Investors could lose 15-20% in this adverse scenario, emphasizing the need for caution.
FAQ
The most severe risk is dividend sustainability, with a payout ratio of 125.75% and Q2 2026 dividends of $2.45 billion exceeding operating cash flow of $835 million, which could lead to a cut. Financial risk includes earnings volatility, as shown by a net loss of $246 million in Q2 2026, driven by a $5.36 billion swing in other expenses. Competitive risk is high, with Eli Lilly and Novo Nordisk dominating obesity, threatening Pfizer's berobenatide opportunity. Macro risk is lower due to a beta of 0.299, but sector rotation away from healthcare could pressure the stock. Company-specific risk includes patent expirations on key drugs like Eliquis, which could erode revenue. Ranked by severity: dividend cut, pipeline failure, competitive share loss, and earnings volatility.
The 12-month forecast includes a bull case (25% probability) targeting $32.00-$35.75, driven by successful obesity pipeline data and earnings normalization. The base case (55% probability) targets $27.50-$30.00, assuming moderate growth and stable dividends. The bear case (20% probability) targets $23.62-$25.00, reflecting pipeline setbacks and a dividend cut. The most likely scenario is the base case, with the key assumption that EPS reaches $2.44 and revenue grows 2-3%. However, the wide analyst target range of $25.00 to $35.75 underscores uncertainty. Investors should watch for Phase 3 berobenatide results and dividend coverage as pivotal factors.
PFE appears undervalued on a forward basis, trading at a forward PE of 9.60x versus a trailing PE of 18.31x, and a PS ratio of 2.26x, which is near multi-year lows compared to 11.84x in Q4 2022. The market is pricing in significant earnings recovery, with consensus EPS of $2.44 versus trailing EPS of $0.055. Relative to peers, PFE's PS ratio is low for a large-cap pharmaceutical with a 70.33% gross margin, but the discount reflects patent cliff risks and pipeline uncertainty. The valuation implies the market expects earnings to normalize, but if estimates prove optimistic, the stock could be fairly valued or even overvalued. Overall, it trades at a discount to its historical average, suggesting undervaluation if execution improves.
From a risk/reward perspective, PFE is a moderate buy for income-focused investors, with a 6.91% dividend yield and a forward PE of 9.60x suggesting undervaluation. The analyst average target of $28.91 implies 4.0% upside, but the high target of $35.75 offers 28.6% potential if pipeline execution succeeds. However, the biggest downside risk is a dividend cut due to a payout ratio of 125.75%, which could drive the stock toward the 52-week low of $23.62, a 15% decline. For long-term investors comfortable with volatility, PFE offers value and income, but near-term catalysts are limited. It is a good buy only if you believe in the earnings recovery and can tolerate the risk of further earnings misses.
PFE is better suited for long-term investment, given its defensive beta of 0.299, 6.91% dividend yield, and deep value on forward earnings (9.60x PE). Short-term trading is less attractive due to low volatility and limited near-term catalysts, with the stock down 4.20% over the past month. The company is in a turnaround phase, and earnings visibility is low, with a net loss in Q2 2026, so a minimum holding period of 2-3 years is recommended to allow for pipeline execution and earnings recovery. Income investors may hold for the dividend, but they must monitor sustainability. Long-term holders could benefit from multiple expansion if EPS normalizes, but patience is required.